Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Death Excess Gives Pause To Merck & Co Keytruda MM Phase III Studies

Executive Summary

Merck & Co has put the brakes on enrolment into two Phase III trials of Keytruda in multiple myeloma to allow it to investigate more deaths in the groups receiving the anti-PD1 product.

Advertisement

Related Content

Deciphering US FDA’s Keytruda Safety Announcement
Merck & Co. Strengthening Its Strong Position In Immuno-Oncology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098932

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel